BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
34 hedge funds and large institutions have $5.29M invested in BRAINSTORM CELL THERAPUTC in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.06% less ownership
Funds ownership: 0.64% → 0.59% (-0.06%)
3% less funds holding
Funds holding: 35 → 34 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
26% less capital invested
Capital invested by funds: $7.11M → $5.29M (-$1.82M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$138K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$74.9K |
| 3 |
Cerity Partners
New York
|
+$42.5K |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$16.8K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$16.8K |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$231K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$210K |
| 3 |
CC
Clearline Capital
New York
|
-$208K |
| 4 |
Renaissance Technologies
New York
|
-$85.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IFAM
26
Institutional & Family Asset Management
Fort Collins,
Colorado
| $6K | +$6.7K | +133 | New |
|
27
UBS Group
Zurich,
Switzerland
| $5K | -$1.21K | -24 | -19% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $4K | -$957 | -19 | -19% |
|
|
ASN
29
Advisory Services Network
Atlanta,
Georgia
| $2K | – | – | – |
|
30
Simplex Trading
Chicago,
Illinois
| $1K | -$1.81K | -36 | -50% |
|
31
Citigroup
New York
| $1K | – | – | – |
|
|
MCM
32
Monument Capital Management
Alexandria,
Virginia
| $1K | – | – | – |
|
33
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
WOC
34
West Oak Capital
Westlake Village,
California
| $473 | +$504 | +10 | New |
|
|
35
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$210K | -3,575 | Closed |
|
|
CC
36
Clearline Capital
New York
| – | -$208K | -3,546 | Closed |
|
|
ARTA
37
A.R.T. Advisors
New York
| – | -$65K | -1,113 | Closed |
|
38
Citadel Advisors
Miami,
Florida
| – | -$59K | -1,002 | Closed |
|
|
RE
39
RBC Europe
London,
United Kingdom
| – | -$1.83K | -31 | Closed |
|
BCLI Hedge Fund Activity: Q1 2018 in Review
34 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2018, worth a combined $5.29M — down 26% from $7.11M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCLI and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $138K. The largest seller was Deutsche Bank, cutting an estimated $231K.
- 34 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2018, down from 35 in Q4 2017.
- Funds reported $5.29M of BRAINSTORM CELL THERAPUTC stock for Q1 2018, down 26% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2018 and 5 closed out, a net change of -1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2018 was Morgan Stanley, an estimated $138K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2018 was Deutsche Bank, an estimated $231K sold.
Based on aggregated 13F filings for Q1 2018.